• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

PharmaJet Tropis becomes exclusive intradermal delivery system for two COVID-19 vaccines

June 28, 2023 By Sean Whooley

PharmaJet Tropis needle-free intradermal injection system
The Tropis needle-free injection system. [Image from PharmaJet]
PharmaJet announced that its Tropis system is now the exclusive intradermal delivery system for two novel COVID-19 vaccines.

Golden, Colorado-based PharmaJet engineers precision delivery systems that overcome the challenges of nucleic acid vaccine delivery. Its Tropis system now offers the delivery of the world’s first plasmid DNA COVID-19 vaccine from Zydus Lifesciences. Exclusively delivered with Tropis, the vaccine demonstrated increased immune response translating into clinical effectiveness, PharmaJet says.

Additionally, Tropis delivers Gennova Biopharmaceutical’s mRNA-based Omicron-specific COVID-19 booster vaccine. The self-amplifying therapeutic enables a low dose of a room temperature, stable mRNA vaccine.

PharmaJet said Tropis already delivered millions of injections in multiple worldwide immunization campaigns. Data repeatedly demonstrated improved immunogenicity for nucleic acid vaccines and therapeutics compared to needle and syringe and electroporation delivery. The company reported efficacy for the Zydus vaccine, plus non-inferior immune response to COVIshield for the Gennova vaccine.

“This marks an important milestone for PharmaJet in that we now have two commercially available nucleic acid-based vaccines in India being exclusively delivered with the Tropis precision delivery system,” said Chris Cappello, PharmaJet president and CEO. “We are well-prepared to rapidly support the demand and look forward to advancing our partnerships and are committed to supporting the advancement of mRNA and DNA vaccines targeting a variety of infectious disease applications for global public health benefit.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: coronavirus, COVID-19, PharmaJet

IN CASE YOU MISSED IT

  • MiniMed claims quick FDA clearance for Fit patch pump
  • Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set
  • Senseonics delivers ‘breakout quarter’ more than doubling Eversense 365 revenue
  • Tandem Diabetes Care names successor as CEO Sheridan retires
  • MiniMed names new CMO ahead of planned retirement

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS